Abbott Laboratories Q4 Earnings: Revenue Growth Overshadowed by Segment Weakness
Abbott Laboratories reported fourth-quarter revenue of $11.46 billion, surpassing expectations, yet shares tumbled 7.35% as investors focused on softening demand in key segments. The medical device giant posted 3% organic sales growth and a 12% increase in adjusted EPS, but Nutrition and Diagnostics underperformed, dragging sentiment lower.
Medical Devices remained a bright spot, with $5.675 billion in revenue and double-digit growth across Electrophysiology, Heart Failure, and Diabetes Care. Market reaction suggests concerns over near-term headwinds outweigh solid fundamentals, as Abbott shifts focus toward 2026 growth targets.